Document Detail

Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors.
MedLine Citation:
PMID:  10887114     Owner:  NLM     Status:  MEDLINE    
In protein S Heerlen, an S-to-P (single-letter amino acid codes) mutation at position 460 results in the loss of glycosylation of N458. This polymorphism has been found to be slightly more prevalent in thrombophilic populations than in normal controls, particularly in cohorts of patients having free protein S deficiency. This suggests that carriers of the Heerlen allele may have an increased risk of thrombosis. We have now characterized the expression in cell cultures of recombinant protein S Heerlen and investigated the anticoagulant functions of the purified recombinant protein in vitro. Protein S Heerlen was synthesized and secreted equally well as wild-type protein S by transiently transfected COS-1 cells. The recombinant protein S Heerlen interacted with conformation-dependent monoclonal antibodies and bound C4b-binding protein to the same extent as wild-type protein S. Protein S Heerlen displayed reduced anticoagulant activity as cofactor to activated protein C (APC) in plasma-based assays, as well as in a factor VIIIa-degradation system. In contrast, protein S Heerlen functioned equally well as an APC cofactor in the degradation of factor Va as wild-type protein S did. However, when recombinant activated factor V Leiden (FVa:Q506) was used as APC substrate, protein S Heerlen was found to be a poor APC cofactor as compared with wild-type protein S. These in vitro results suggest a possible mechanism of synergy between protein S Heerlen and factor V Leiden that might be involved in the pathogenesis of thrombosis in individuals carrying both genetic traits. (Blood. 2000;96:523-531)
T K Giri; T Yamazaki; N Sala; B Dahlbäck; P G de Frutos
Related Documents :
10593904 - C-terminal residues 621-635 of protein s are essential for binding to factor va.
23273574 - Endogenous aggregates of amyloidogenic cystatin c variant are removed by thp-1 cells in...
23751494 - Spatiotemporal control of popz localization through cell cycle-coupled multimerization.
1184964 - Cationic proteins of human granulocytes. vi. effects on the complement system and media...
7119004 - Mammalian eyes and associated tissues contain molecules that are immunologically relate...
16250904 - The ubiquitin-proteasome system and neurodegenerative disorders.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood     Volume:  96     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  2000 Jul 
Date Detail:
Created Date:  2000-08-17     Completed Date:  2000-08-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  523-31     Citation Subset:  AIM; IM    
Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital, Malmö, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal
COS Cells
Complement C4a / metabolism
Factor V / metabolism*
Factor VIIIa / metabolism
Factor Va / metabolism
Gene Expression
Protein C / metabolism*
Protein Conformation
Protein S / genetics*,  metabolism
Recombinant Proteins / metabolism
Risk Factors
Thrombophilia / genetics*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Protein C; 0/Protein S; 0/Recombinant Proteins; 0/factor V Leiden; 65522-14-7/Factor Va; 72175-66-7/Factor VIIIa; 80295-49-4/Complement C4a; 9001-24-5/Factor V

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin...
Next Document:  Surface expression of glycoprotein ib alpha is dependent on glycoprotein ib beta: evidence from a no...